Research Progress on the Pathogenesis and Treatment of Neoatherosclerosis

Yi-shan Guo, Ning Yang, Zhen Wang, Yu-miao Wei

Current Medical Science ›› 2024, Vol. 44 ›› Issue (4) : 680-685.

Current Medical Science ›› 2024, Vol. 44 ›› Issue (4) : 680-685. DOI: 10.1007/s11596-024-2915-x
Review

Research Progress on the Pathogenesis and Treatment of Neoatherosclerosis

Author information +
History +

Abstract

Neoatherosclerosis (NA) within stents has become an important clinical problem after coronary artery stent implantation. In-stent restenosis and in-stent thrombosis are the two major complications following coronary stent placement and seriously affect patient prognosis. As the common pathological basis of these two complications, NA plaques, unlike native atherosclerotic plaques, often grow around residual oxidized lipids and stent struts. The main components are foam cells formed by vascular smooth muscle cells (VSMCs) engulfing oxidized lipids at lipid residue sites. Current research mainly focuses on optical coherence tomography (OCT) and intravascular ultrasound (IVUS), but the specific pathogenesis of NA is still unclear. A thorough understanding of the pathogenesis and pathological features of NA provides a theoretical basis for clinical treatment. This article reviews the previous research of our research group and the current situation of domestic and foreign research.

Cite this article

Download citation ▾
Yi-shan Guo, Ning Yang, Zhen Wang, Yu-miao Wei. Research Progress on the Pathogenesis and Treatment of Neoatherosclerosis. Current Medical Science, 2024, 44(4): 680‒685 https://doi.org/10.1007/s11596-024-2915-x

References

[1]
Yahagi K, Kolodgie FD, Otsuka F, et al.. Pathophysiology of native coronary, vein graft, and in-stent atherosclerosis. Nat Rev Cardiol, 2016, 13(2): 79-98
CrossRef Google scholar
[2]
Mazin I, Paul G, Asher E, et al.. Neoatherosclerosis - From basic concept to clinical implication. Thromb Res, 2019, 178: 12-16
CrossRef Google scholar
[3]
Borovac JA, D’Amario D, Vergallo R, et al.. Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge. Eur Heart J Cardiovasc Pharmacother, 2019, 5(2): 105-116
CrossRef Google scholar
[4]
Libby P. Inflammation in Atherosclerosis—No Longer a Theory. Clin Chem, 2021, 67(1): 131-142
CrossRef Google scholar
[5]
Libby P. Targeting Inflammatory Pathways in Cardiovascular Disease: The Inflammasome, Interleukin-1, Interleukin-6 and Beyond. Cells, 2021, 10(4): 951
CrossRef Google scholar
[6]
Raggi P, Genest J, Giles JT, et al.. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis, 2018, 276: 98-108
CrossRef Google scholar
[7]
Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature, 2011, 473(7347): 317-325
CrossRef Google scholar
[8]
Chen ZY, Matsumura M, Mintz GS, et al.. Prevalence and Impact of Neoatherosclerosis on Clinical Outcomes After Percutaneous Treatment of Second-Generation Drug-Eluting Stent Restenosis. Circ Cardiovasc Interv, 2022, 15(9): e011693
CrossRef Google scholar
[9]
Mach F, Baigent C, Catapano AL, et al.. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J, 2020, 41(1): 111-188
CrossRef Google scholar
[10]
Raber L, Serruys PW. Late vascular response following drug-eluting stent implantation. JACC Cardiovasc Interv, 2011, 4(10): 1075-1078
[11]
Andreou I, Stone PH. In-Stent Atherosclerosis at a Crossroads: Neoatherosclerosis or Paleoatherosclerosis?. Circulation, 2016, 134(19): 1413-1415
CrossRef Google scholar
[12]
Yuan X, Jiang M, Feng H, et al.. The effect of sex differences on neointimal characteristics of in-stent restenosis in drug-eluting stents: An optical coherence tomography study. Heliyon, 2023, 9(8): e19073
CrossRef Google scholar
[13]
Nakamura D, Dohi T, Ishihara T, et al.. Predictors and outcomes of neoatherosclerosis in patients with in-stent restenosis. EuroIntervention, 2021, 17(6): 489-496
CrossRef Google scholar
[14]
Lee SY, Hur SH, Lee SG, et al.. Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation. Circ Cardiovasc Interv, 2015, 8(2): e001878
CrossRef Google scholar
[15]
Torii R, Stettler R, Raber L, et al.. Implications of the local hemodynamic forces on the formation and destabilization of neoatherosclerotic lesions. Int J Cardiol, 2018, 272: 7-12
CrossRef Google scholar
[16]
Torii S, Jinnouchi H, Sakamoto A, et al.. Drug-eluting coronary stents: insights from preclinical and pathology studies. Nat Rev Cardiol, 2020, 17(1): 37-51
CrossRef Google scholar
[17]
Otsuka F, Byrne RA, Yahagi K, et al.. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J, 2015, 36(32): 2147-2159
CrossRef Google scholar
[18]
Nakazawa G, Otsuka F, Nakano M, et al.. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol, 2011, 57(11): 1314-1322
CrossRef Google scholar
[19]
Jang IK, Tearney GJ, MacNeill B, et al.. In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography. Circulation, 2005, 111(12): 1551-1555
CrossRef Google scholar
[20]
Nakamura D, Attizzani GF, Toma C, et al.. Failure Mechanisms and Neoatherosclerosis Patterns in Very Late Drug-Eluting and Bare-Metal Stent Thrombosis. Circ Cardiovasc Interv, 2016, 9(9): e003785
CrossRef Google scholar
[21]
Yabushita H, Bouma BE, Houser SL, et al.. Characterization of human atherosclerosis by optical coherence tomography. Circulation, 2002, 106(13): 1640-1645
CrossRef Google scholar
[22]
Ali ZA, Roleder T, Narula J, et al.. Increased thin-cap neoatheroma and periprocedural myocardial infarction in drug-eluting stent restenosis: multimodality intravascular imaging of drug-eluting and bare-metal stents. Circ Cardiovasc Interv, 2013, 6(5): 507-517
CrossRef Google scholar
[23]
Nusca A, Viscusi MM, Piccirillo F, et al.. In Stent Neoatherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. Life (Basel), 2022, 12(3): 393
[24]
Park SJ, Kang SJ, Virmani R, et al.. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol, 2012, 59(23): 2051-2057
CrossRef Google scholar
[25]
Borovac JA, D’Amario D, Niccoli G. Neoatherosclerosis and Late Thrombosis After Percutaneous Coronary Intervention: Translational Cardiology and Comparative Medicine from Bench to Bedside. Yale J Biol Med, 2017, 90(3): 463-470
[26]
Nakazawa G, Vorpahl M, Finn AV, et al.. One step forward and two steps back with drug-eluting-stents: from preventing restenosis to causing late thrombosis and nouveau atherosclerosis. JACC Cardiovasc Imaging, 2009, 2(5): 625-628
CrossRef Google scholar
[27]
Handelsman Y, Jellinger PS, Guerin CK, et al.. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. Endocr Pract, 2020, 26(10): 1196-1224
CrossRef Google scholar
[28]
Farb A, Kolodgie FD, Hwang JY, et al.. Extracellular matrix changes in stented human coronary arteries. Circulation, 2004, 110(8): 940-947
CrossRef Google scholar
[29]
Araki T, Nakamura M, Sugi K. Characterization of in-stent neointimal tissue components following drug-eluting stent implantation according to the phase of restenosis using a 40-MHz intravascular ultrasound imaging system. J Cardiol, 2014, 64(6): 423-429
CrossRef Google scholar
[30]
Cui Y, Liu Y, Zhao F, et al.. Neoatherosclerosis after Drug-Eluting Stent Implantation: Roles and Mechanisms. Oxid Med Cell Longev, 2016, 2016: 5924234
CrossRef Google scholar
[31]
Wang H, Wang Q, Hu J, et al.. Global research trends in in-stent neoatherosclerosis: A CiteSpace-based visual analysis. Front Cardiovasc Med, 2022, 9: 1025858
CrossRef Google scholar
[32]
Wang ZW, Chen J, Zeng ZL, et al.. The LOX-1 receptor ectopically expressed in the liver alleviates atherosclerosis by clearing Ox-LDL from the circulation. Mol Med, 2022, 28(1): 26
CrossRef Google scholar
[33]
Wang ZW, Guo XP, Zhang Q, et al.. Elimination of Ox-LDL through the liver inhibits advanced atherosclerotic plaque progression. Int J Med Sci, 2021, 18(16): 3652-3664
CrossRef Google scholar
[34]
Zhang Q, Du GH, Tong L, et al.. Overexpression of LOX-1 in hepatocytes protects vascular smooth muscle cells from phenotype transformation and wire injury induced carotid neoatherosclerosis through ALOX15. Biochim Biophys Acta Mol Basis Dis, 2023, 1869(8): 166805
CrossRef Google scholar

Accesses

Citations

Detail

Sections
Recommended

/